Abstract

Alzheimer’s disease is one of the most common chronic neurodegenerative disorders. Despite several in vivo and clinical studies, the cause of the disease is poorly understood. Currently, amyloid β (Aβ) peptide and its tendency to assemble into soluble oligomers are known as a main pathogenic event leading to the interruption of synapses and brain degeneration. Targeting neurotoxic Aβ oligomers can help recognize the disease at an early stage or it can be a potential therapeutic approach. Unnatural β-peptidic foldamers are successfully used against many different protein targets due to their favorable structural and pharmacokinetic properties compared to small molecule or protein-like drug candidates. We have previously reported a tetravalent foldamer-dendrimer conjugate which can selectively bind Aβ oligomers. Taking advantage of multivalency and foldamers, we synthesized different multivalent foldamer-based conjugates to optimize the geometry of the ligand. Isothermal titration calorimetry (ITC) was used to measure binding affinity to Aβ, thereafter 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) based tissue viability assay and impedance-based viability assay on SH-SY5Y cells were applied to monitor Aβ toxicity and protective effects of the compounds. Important factors for high binding affinity were determined and a good correlation was found between influencing the valence and the capability of the conjugates for Aβ binding.

Highlights

  • Alzheimer’s disease (AD) is one of the most common forms of senile dementia and it belongs to the aggregation-associated disorders [1,2]

  • We have reported a tetravalent β-peptidic dendrimer conjugate which can selectively recognize the low molecular weight (LMW) fraction of amyloid β (Aβ) (1–42) and binds to peptide assemblies without remodeling its conformation or disaggregating oligomers into monomers with random coil structures

  • To study the role of certain structure elements in the binding affinity, a set of new foldamer sequences were designed (Figure 2) and ligated to lysine-dendron scaffolds having a focal symmetry. This template with biotin affinity tag can be synthesized by solid phase peptide synthesis and immobilized on a streptavidin coated support such as the surface of the ELISA plate [36]

Read more

Summary

Introduction

Alzheimer’s disease (AD) is one of the most common forms of senile dementia and it belongs to the aggregation-associated disorders [1,2]. The pathology of AD is not yet fully understood and simultaneous effects of several different factors may be responsible for the onset of the disease Several potential disease-modifying therapeutic strategies are at preclinical or clinical stages of development, aiming either to prevent the formation of the protein aggregates and/or to eliminate them. These attempts involve the inhibition of the biosynthesis of Aβ peptides by β- and γ-secretase modulators [8,9], the removal of the produced

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call